Prosecution Insights
Last updated: November 04, 2026
Application No. 18/655,775

QUADRANTANOPIAL OCCLUSIVE LENSES AND METHOD OF USE

Non-Final OA §102§112
Filed
May 06, 2024
Priority
Feb 17, 2022 — provisional 63/311,097 +1 more
Examiner
TRAN, LARA LINH
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Rosenthal Holdings LLC
OA Round
1 (Non-Final)
23%
Grant Probability
At Risk
1-2
OA Rounds
1y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants only 23% of cases
23%
Career Allowance Rate
3 granted / 13 resolved
-46.9% vs TC avg
Strong +91% interview lift
Without
With
+90.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
31 currently pending
Career history
59
Total Applications
across all art units

Statute-Specific Performance

§101
4.7%
-35.3% vs TC avg
§103
41.9%
+1.9% vs TC avg
§102
27.9%
-12.1% vs TC avg
§112
23.8%
-16.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 13 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 5, 12, 13, 16, and 17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 2, it recites the limitation "the quality of performance". There is insufficient antecedent basis for this limitation in the claim. Regarding claim 5, it recites the limitation “the patient’s eye movements”. There is insufficient antecedent basis for this limitation in the claim. Regarding claim 12, it recites the limitation “wherein generating a lens”. There is insufficient antecedent basis for this limitation in the claim. Regarding claims 16 and 17, it recites the limitation “the field areas”. There is insufficient antecedent basis for this limitation in the claims. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-17 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Malchano (US 20180133507 A1). Regarding claim 1, Malchano teaches a therapeutic method of improving neurological performance of a patient (“methods for treating cognitive dysfunction in a subject in need”, abstract) comprising the steps of: Performing a vision zone assessment test to identify a field area of a patient’s field of view having a selected characteristic (“subject assessment monitor can, via one or more of the measurement device, measure a task response of the subject to the administered assessment”, paragraph [0033]); Based on the identified field area, providing an appliance (frame 400, Fig. 4A) having a non-transparent optical characteristic associated with the field area (“lens or solid material 425 can provide visibility through the frame 400…can provide full visibility, or limited visibility…can be tinted, opaque, or switchable”, paragraph [0268]); The patient wearing the appliance (“frame 400…can be placed on a subject or user”, paragraph [0267]); and While the patient is wearing the appliance, the patient performing a selected activity associated with the neurological performance (“cognitive function test may be administered to the subject, and the subject’s test results can be stored as the subject cognitive function data 2715”, paragraph [0675]). Regarding claim 2, Malchano teaches the neurological performance being associated with the quality of performance of the selected activity (“subject cognitive function data 2715 indicates that the subject’s cognitive function is deteriorating over time”, paragraph [0678]). Regarding claim 3, Malchano teaches the selected activity being a physical activity (“feedback on the subject can include…activity (e.g., sitting, laying down, walking, biking or driving)”, paragraph [0632]). Regarding claim 4, Malchano teaches performing a vision zone assessment test including moving a visual target about the patient’s field of view (“visual signaling component 150 can stimulate discrete portions of the cortex by modulating the presentation of the stimuli to target specific or general regions of interest…field of view”, paragraph [0286]). Regarding claim 5, Malchano teaches performing a vision zone assessment test including observing the patient’s eye movements in response to a moving visual stimulus (“feedback monitor 135 can track a person’s eye movement to identify a level of attention”, paragraph [0303]). Regarding claim 6, Malchano teaches the selected characteristic being abnormal eye movement when directed to a selected direction (“feedback component 1660 can compare the eye direction…can compare the current eye movement with the historical eye movement to identify a deviation”, paragraph [0583]). Regarding claim 7, Malchano teaches the non-transparent optical characteristic having opacity (“the lens, solid material, or cover 425 can be…opaque”, paragraph [0266]). Regarding claim 8, Malchano teaches the non-transparent optical characteristic having translucency (“the lens, solid material, or cover 425 can be…semi-transparent”, paragraph [0266]). Regarding claim 9, Malchano teaches the non-transparent optical characteristic having reduced transmissivity (“the lens, solid material, or cover 425 can…completely block out external light”, paragraph [0266]). Regarding claim 10, Malchano teaches the appliance being eyewear having a frame and a lens (“frame 400 can be configured to be worn by the person…can include or hold a lens 425”, paragraph [0266]; Fig. 4A). Regarding claim 11, Malchano teaches providing the appliance including generating a lens having the non-transparent optical characteristic in an area registered with the patient’s field area (“the lens or solid material 425 can provide visibility through the frame 400…NSS 105 can switch or change the lens or solid material 425 to improve adherence, such as by increasing visibility so the subject is more aware of the surrounding environment”, paragraph [0268]). Regarding claims 12 and 13, Malchano taches generating a lens including applying an optical material to the lens, and the optical material is selected from a group including inks, films, tapes, diffusants, and masks (“a diffuser element can be added between the light source 305 and the eyes or fovea of the subject”, paragraph [0269]). Regarding claim 14, Malchano teaches the vision zone assessment test being an optometric test (“assessment administration module 3110 can select the assessment policy specifying that visual assessments are to be first administered”, paragraph [0769]). Regarding claim 15, Malchano teaches the selected activity being an athletic activity (“feedback on the subject can include…activity (e.g., sitting, laying down, walking, biking or driving)”, paragraph [0632]). Regarding claims 16 and 17, Malchano teaches the field areas being different for the patient’s right eyes and left eyes, as well as the field areas being different between a right side and left side of the patient’s field of view (“NSS 105 can direct light pulses to a single eye or both eyes”, paragraph [0270]). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to LARA LINH TRAN whose telephone number is (571)272-3598. The examiner can normally be reached 7:30am-5:00pm M-F. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Alexander Valvis can be reached at 5712724233. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /L.L.T./Examiner, Art Unit 3791 /CHRISTINE H MATTHEWS/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

May 06, 2024
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12702852
APPARATUS FOR TREATING URINARY INCONTINENCE USING MAGNETIC FIELD
3y 6m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 1 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
23%
Grant Probability
99%
With Interview (+90.9%)
3y 6m (~1y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 13 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month